Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
CRESTOR-specific LDL/CV-risk, dosing-dependence, and safety statements are partially supported by the provided label excerpts. However, many claims about Lipitor/atorvastatin, switching between the two, and cross-drug selection guidance are absent or only indirectly supported in the provided CRESTOR label text, and the prompt lacks Lipitor label text to verify those assertions.
Category Scores
Accurate Statements
For these medications, muscle-related symptoms (myalgia) can occur.
CRESTOR myopathy/rhabdomyolysis warning includes muscle pain and related symptoms (5.1, 17). Lipitor/atorvastatin equivalence is not supported.
For these medications, rhabdomyolysis is a rare possible muscle-related adverse effect.
CRESTOR may cause rhabdomyolysis; acute kidney injury and rare fatalities have occurred (5.1). Label does not provide atorvastatin/Lipitor wording.
For these medications, liver enzyme elevations can occur.
Increases in serum transaminases reported with CRESTOR (5.3). No comparable Lipitor/atorvastatin statement is provided in the excerpts.
For these medications, possible blood sugar effects can occur in some patients.
Increases in HbA1c and fasting serum glucose levels reported with statins including CRESTOR (5.5). Excerpt does not provide Lipitor/atorvastatin-specific wording.
The right comparison for LDL goal achievement is usually dose-to-dose effectiveness and prior cholesterol response, not brand name.
Absent from provided CRESTOR excerpts; comparative dose response exists in clinical studies but the stated clinical rule is not in the excerpt.
Unsupported Statements
Lipitor is a brand of statin medication that contains atorvastatin.
No Lipitor/atorvastatin identity information is present in the provided CRESTOR label excerpts.
Crestor and Lipitor are both used to lower LDL cholesterol.
CRESTOR LDL-C lowering is supported; Lipitor portion is not supported in the provided excerpts because no atorvastatin/Lipitor indication text is included.
Crestor and Lipitor are both used to reduce cardiovascular risk.
CRESTOR CV-risk reduction indication is supported (1), but Lipitor/atorvastatin CV-risk indication is not supported in the provided excerpts.
Clinicians can switch between rosuvastatin and atorvastatin.
No switching guidance between rosuvastatin and atorvastatin is provided in the excerpts.
The right comparison for LDL goal achievement is usually dose-to-dose effectiveness and prior cholesterol response, not brand name.
No such guidance appears in the provided CRESTOR label excerpts.
Clinicians may choose Crestor or Lipitor based on a patient’s LDL response to a prior statin.
No label content in the provided excerpts addresses choosing between rosuvastatin and atorvastatin based on prior statin LDL response.
Clinicians may choose Crestor or Lipitor based on side effects such as muscle symptoms.
The excerpts describe CRESTOR muscle risk and reporting, but do not provide guidance to choose between rosuvastatin and atorvastatin based on muscle symptoms.
Clinicians may choose Crestor or Lipitor based on drug-drug interactions involving statins.
The excerpts provide CRESTOR interaction/dose modification information, but do not state cross-drug choice between CRESTOR and Lipitor based on interactions.
Clinicians may choose Crestor or Lipitor based on kidney function considerations.
The excerpts include CRESTOR dosing in renal impairment, but do not provide guidance for choosing between rosuvastatin and atorvastatin based on kidney function.
Both rosuvastatin and atorvastatin are widely available as generics in many markets.
No label content in the excerpts addresses generic availability.
The timing of brand exclusivity, patent challenges, and filings affecting supply can vary by country.
No label content in the excerpts addresses exclusivity, patents, filings, or supply by country.
Contradictions
Low
AI Statement
The right comparison for LDL goal achievement is usually dose-to-dose effectiveness and prior cholesterol response, not brand name.
Label Reference
No direct contradiction, but it is not supported by the provided label excerpts.
Important Omissions
Contraindications, boxed warning status, and key warnings/pregnancy/lactation/pediatric-specific safety details for CRESTOR (and any relevant statements for Lipitor/atorvastatin) are not provided in the prompt’s evaluated material set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Cross-drug switching/selection and Lipitor-specific comparative guidance are largely unsupported by the provided CRESTOR label excerpts and cannot be verified because Lipitor label text is not included. This creates risk of unsafe extrapolation from non-verified statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Many claims about Lipitor/atorvastatin and switching/choice between rosuvastatin and atorvastatin are absent or cannot be verified against the provided label excerpts (which are CRESTOR-focused).
Suggested Improvement
Restrict statements to CRESTOR-supported label content in the provided excerpts; remove or qualify Lipitor/atorvastatin and cross-drug switching/selection claims unless the Lipitor prescribing information text is supplied and verified. Use CRESTOR-specific monitoring wording (e.g., 'consider testing...when clinically indicated' rather than 'usually monitored') consistent with the excerpt.